Market Place
Sourcing Support
PTC Therapeutics signs up to $2.9 B licensing deal with Novartis
03 Dec 2024 //
REUTERS
PTC Therapeutics to Sell Priority Review Voucher for $150 Million
27 Nov 2024 //
PR NEWSWIRE
PTC Therapeutics discontinues ALS drug after trial failure
27 Nov 2024 //
REUTERS
PTC Therapeutics Reports Inducement Grants Under Nasdaq 5635(c)(4)
25 Nov 2024 //
PR NEWSWIRE
FDA approves PTC Therapeutics` gene therapy for ultra-rare disorder
14 Nov 2024 //
REUTERS
PTC Reports Q3 2024 Financials & Corporate Update
07 Nov 2024 //
PR NEWSWIRE
PTC Therapeutics to Participate at Upcoming Investor Conferences
04 Nov 2024 //
PR NEWSWIRE
PTC Therapeutics Announces FDA Acceptance of Translarna™ NDA
30 Oct 2024 //
PR NEWSWIRE
PTC Therapeutics Reports Inducement Grants Under Nasdaq Rule
25 Oct 2024 //
PR NEWSWIRE
PTC Therapeutics To Host Q3 2024 Results Conference Call
24 Oct 2024 //
PR NEWSWIRE
Europe`s CHMP backs Novo`s FDA-rejected hemophilia treatment
19 Oct 2024 //
FIERCE PHARMA
CHMP Maintains Negative Opinion on Translarna™ Reexamination
18 Oct 2024 //
PR NEWSWIRE
PTC Therapeutics Announces FDA Date For Sepiapterin
14 Oct 2024 //
PR NEWSWIRE
PTC bounces back with positive data on FA prospect vatiquinone
08 Oct 2024 //
FIERCE BIOTECH
PTC Announces Positive Results For Vatiquinone Ataxia Program
08 Oct 2024 //
PR NEWSWIRE
PTC Therapeutics` NDA for Sepiapterin Accepted for Phenylketonuria
01 Oct 2024 //
PR NEWSWIRE
FDA Grants Fast Track To PTC518 For Huntington`s
26 Sep 2024 //
PR NEWSWIRE
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12 Sep 2024 //
PR NEWSWIRE
PTC Therapeutics to Participate at Upcoming Investor Conferences
28 Aug 2024 //
PR NEWSWIRE
PTC Therapeutics Reports Q2 2024 Results And Corporate Update
08 Aug 2024 //
PR NEWSWIRE
PTC Therapeutics To Host Q2 2024 Financial Results Call
25 Jul 2024 //
PR NEWSWIRE
EU`s drug regulator again rejects Apellis` eye med and PTC`s Translarna
02 Jul 2024 //
FIERCE PHARMA
CHMP Issues Negative Opinion On Translarna Following European Commission Review
28 Jun 2024 //
PR NEWSWIRE
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
21 Jun 2024 //
PR NEWSWIRE
PIVOT-HD Shows Positive 12-Month Biomarker And Clinical Data In Huntington`s
20 Jun 2024 //
PR NEWSWIRE
PTC Therapeutics to Participate at Upcoming Investor Conference
30 May 2024 //
PR NEWSWIRE
PTC Therapeutics Announces Validation of Sepiapterin European MAA
28 May 2024 //
PR NEWSWIRE
PTC gets another chance to keep Translarna`s EU authorization
21 May 2024 //
FIERCE PHARMA
PTC: EU Returns Translarna Opinion To CHMP For Re-Evaluation
20 May 2024 //
PR NEWSWIRE
PTC Announces FDA Acceptance, Priority Review Of Upstaza BLA
14 May 2024 //
PR NEWSWIRE
PTC Therapeutics to Participate at Upcoming Investor Conferences
02 May 2024 //
PR NEWSWIRE
Technical Analysis of PTC Therapeutics
29 Apr 2024 //
TRADINGVIEW
PTC Therapeutics Q1 2024 Results, Corporate Update
25 Apr 2024 //
PR NEWSWIRE
PTC Therapeutics Inducement Grants Under Nasdaq 5635(c)(4)
23 Apr 2024 //
PRESS RELEASE
PTC Therapeutics To Host Q1 2024 Results Call
11 Apr 2024 //
PR NEWSWIRE
PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA
28 Mar 2024 //
PR NEWSWIRE
PTC Therapeutics Provides Key Regulatory Updates
19 Mar 2024 //
PR NEWSWIRE
ClearPoint Congratulates its Partner PTC of BLA Sub to FDA for Upstaza
19 Mar 2024 //
GLOBENEWSWIRE
After pair of failures, PTC finds path for Friedreich ataxia med
01 Mar 2024 //
FIERCE BIOTECH
PTC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
29 Feb 2024 //
PRESS RELEASE
PTC Therapeutics to Participate at Upcoming Investor Conferences
27 Feb 2024 //
PR NEWSWIRE
PTC to Host Conference to Discuss Q4 and Full Year 2023 Financial Results
15 Feb 2024 //
PR NEWSWIRE
PTC`s Emflaza to face generics this month post Aurobindo FDA nod
12 Feb 2024 //
FIERCE PHARMA
PTC`s re-examination bid for Translarna falls short in Europe
25 Jan 2024 //
FIERCE PHARMA
PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline
08 Jan 2024 //
PR NEWSWIRE
PTC Therapeutics to Participate at 42nd Annual J.P. Morgan Conference
03 Jan 2024 //
PR NEWSWIRE
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
14 Dec 2023 //
PR NEWSWIRE
PTC Therapeutics Provides Updates on Translarna™ Regulatory Activities
05 Dec 2023 //
PR NEWSWIRE
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Nov 2023 //
PR NEWSWIRE
FDA demands data on 2 PTC candidates, delaying filing
27 Oct 2023 //
FIERCE BIOTECH
PTC Therapeutics Reports Third Quarter Financial Results
26 Oct 2023 //
PR NEWSWIRE
PTC Announces Evrysdi Agreement with Royalty Pharma for Up To $1.5 Billion
20 Oct 2023 //
PR NEWSWIRE
Why PTC Therapeutics Soared 15% Higher Today
19 Oct 2023 //
FOOL
PTC Therapeutics to Host Conference to Discuss?Q3 2023 Financial Results?
16 Oct 2023 //
PR NEWSWIRE
PTC cuts 25% of its workforce to save money amid big company revamp
29 Sep 2023 //
ENDPTS
PTC Announces Further Prioritization and Associated Reduction in Workforce
28 Sep 2023 //
PR NEWSWIRE
Market withdrawal looms for PTC`s DMD drug in Europe
16 Sep 2023 //
FIERCE PHARMA
CHMP Delivers Opinion on Translarna™ for Conversion to Full Authorization
15 Sep 2023 //
PR NEWSWIRE
PTC Therapeutics` 2023 STRIVE Awards Program Funds Initiatives Supporting the Duchenne Patient Community
07 Sep 2023 //
PR NEWSWIRE
PTC Therapeutics to Participate at Upcoming Investor Conferences
30 Aug 2023 //
PR NEWSWIRE
